440 related articles for article (PubMed ID: 18163939)
1. Managing prostate cancer: the role of hormone therapy.
Ramirez ML; Keane TE; Evans CP
Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
3. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
4. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
6. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
7. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
8. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
Akaza H; Hirao Y; Labrie F; Soloway MS
Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
[TBL] [Abstract][Full Text] [Related]
9. Hormonal therapy for prostate cancer: past, present and future.
el-Rayes BF; Hussain MH
Expert Rev Anticancer Ther; 2002 Feb; 2(1):37-47. PubMed ID: 12113064
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation: clinical experience and practical applications.
Wright JL; Higano CS; Lin DW
Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
[TBL] [Abstract][Full Text] [Related]
11. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer: the role of hormonal therapy.
Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
14. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
Matveev BP; Bukharkin BV
Urologiia; 2003; (6):6-10. PubMed ID: 14708235
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
17. Primary combined androgen blockade in localized disease and its mechanism.
Namiki M; Kitagawa Y; Mizokami A; Koh E
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
[TBL] [Abstract][Full Text] [Related]
18. [Hormone therapy for prostate cancer].
Théodore C
Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].
Bolla M; Artignan X; Fourneret P; Brochon D; Ringeisen F; Descotes JL
Bull Cancer; 2006 Nov; 93(11):1101-5. PubMed ID: 17145579
[TBL] [Abstract][Full Text] [Related]
20. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
